PE20071230A1 - Combinaciones y metodos de inhibidores del vhc - Google Patents

Combinaciones y metodos de inhibidores del vhc

Info

Publication number
PE20071230A1
PE20071230A1 PE2007000143A PE2007000143A PE20071230A1 PE 20071230 A1 PE20071230 A1 PE 20071230A1 PE 2007000143 A PE2007000143 A PE 2007000143A PE 2007000143 A PE2007000143 A PE 2007000143A PE 20071230 A1 PE20071230 A1 PE 20071230A1
Authority
PE
Peru
Prior art keywords
dimethyl
amino
rotamer
tautomer
interferon
Prior art date
Application number
PE2007000143A
Other languages
English (en)
Inventor
Emilio Anthony Emini
Michael James Flint
Anita Yee Mei Howe
Bruce A Malcolm
Stanley L Mullen
Robert Orville Ralston
Xiao Tong
Original Assignee
Schering Corp
Viropharma Inc
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Viropharma Inc, Wyeth Corp filed Critical Schering Corp
Publication of PE20071230A1 publication Critical patent/PE20071230A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL ARN DEL VIRUS DE LA HEPATITIS C (VHC) TAL COMO 5-CICLOPROPIL-2-(4-FLUORO-FENIL)-6-[(2-HIDROXIETIL)-METANSULFONILAMINO]-BENZOFURAN-3-CARBOXILICO O UN ROTAMERO, TAUTOMERO U OTRA FORMA ISOMERICA O UNA SAL DE LOS MISMOS Y UN INHIBIDOR DE LA PROTEASA DEL VHC TAL COMO (1R,5S)-N-[3-AMINO-1-(CICLOBUTILMETIL)-2,3-DIOXOPROPIL]-3-[2(S)-[[[(1,1-DIMETIETIL)AMINO]CARBONIL]AMINO]3,3-DIMETIL-1-OXOBUTIL]6.6-DIMETIL-3-AZABICICLO[3.1.0]HEXAN-2(S)-CARBOXAMIDA O UN ENANTIOMERO, ESTEREOISOMERO, ROTAMERO, TAUTOMERO, COMPUESTO RACEMICO U OTRA FORMA ISOMERICA O UNA SAL DE LOS MISMOS. LA COMPOSICION PUEDE CONTENER ADEMAS OTRO AGENTE BIOLOGICAMENTE ACTIVO TAL COMO INTERFERON, PEG-INTERFERON O RIBAVIRINA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LA HEPATITIS C Y TRASTORNOS AFINES
PE2007000143A 2006-02-09 2007-02-09 Combinaciones y metodos de inhibidores del vhc PE20071230A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77192706P 2006-02-09 2006-02-09
US84178906P 2006-08-30 2006-08-30

Publications (1)

Publication Number Publication Date
PE20071230A1 true PE20071230A1 (es) 2008-01-16

Family

ID=38261665

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000143A PE20071230A1 (es) 2006-02-09 2007-02-09 Combinaciones y metodos de inhibidores del vhc

Country Status (7)

Country Link
US (1) US20070224167A1 (es)
EP (1) EP1981523A2 (es)
AR (1) AR059430A1 (es)
CL (1) CL2007000361A1 (es)
PE (1) PE20071230A1 (es)
TW (1) TW200808308A (es)
WO (1) WO2007092645A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007286754A1 (en) * 2006-08-25 2008-02-28 Viropharma Incorporated Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
WO2009021121A2 (en) * 2007-08-08 2009-02-12 Wyeth Identification and characterization of hcv replicon variants with reduced susceptibility to a combination of polymerase and protease inhibitors, and methods related thereto
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
CA2709535A1 (en) 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Hcv protease inhibitors and uses thereof
AU2008340261C1 (en) * 2007-12-21 2015-12-10 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
WO2009101022A1 (en) * 2008-02-14 2009-08-20 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
TW201023858A (en) * 2008-09-18 2010-07-01 Ortho Mcneil Janssen Pharm Synergistic combinations of a macrocyclic inhibitor of HCV and a nucleoside
WO2010031832A2 (en) * 2008-09-18 2010-03-25 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
WO2010117939A1 (en) * 2009-04-06 2010-10-14 Schering Corporation Hcv inhibitor and therapeutic agent combinations
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
BR112018017228A2 (pt) 2016-03-04 2019-02-05 Univ Leland Stanford Junior composições e métodos para regeneração do músculo usando prostaglandina e2
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE911129A1 (en) * 1990-04-04 1991-10-09 Chiron Corp Hepatitis c virus protease
PL206255B1 (pl) * 2000-07-21 2010-07-30 Dendreon Corporationdendreon Corporation Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii
CA2504344A1 (en) * 2002-11-01 2004-05-21 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
CN1894276B (zh) * 2003-10-27 2010-06-16 威特克斯医药股份有限公司 Hcv ns3-ns4a蛋白酶抗药性突变体
US20070258946A1 (en) * 2003-12-23 2007-11-08 Blatt Lawrence M Combination Therapy for Treating Hepatitis C Virus Infection

Also Published As

Publication number Publication date
TW200808308A (en) 2008-02-16
US20070224167A1 (en) 2007-09-27
WO2007092645A2 (en) 2007-08-16
WO2007092645A3 (en) 2007-10-04
CL2007000361A1 (es) 2008-01-25
AR059430A1 (es) 2008-04-09
EP1981523A2 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
PE20071230A1 (es) Combinaciones y metodos de inhibidores del vhc
HRP20191939T1 (hr) Postupci za liječenje hepatitisa c
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
PE20060309A1 (es) (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l
PE20140038A1 (es) Compuestos antivirales
CR7432A (es) Amidas sustituidas activas del receptor de canabinoide-1
UY28525A1 (es) Péptidos macrociclicos activos contra en virus de la hepatitis c
CL2012001449A1 (es) Uso de combinaciones del compuesto n-[(ciclopentiloxi)carbonil]-3-metil-l-valiol-(4r)-4-({8-bromo-2-[2-(isobutirilamino)-1,3-tiazol-4-il]-7-metoxi-4-quinolinil}oxi)-n-[(1r,2s)-1-carboxi-2-vinilciclopropil]-l-prolinamida; y envase que comprende las formas de dosificacion.
JP2009506071A5 (es)
NZ592705A (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
JP2005532372A5 (es)
RU2010141542A (ru) Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
WO2007056142A3 (en) Methods of preventing the serotonin syndrome and compositions for use therefor
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
EA200870060A1 (ru) Эмульсия бутилфталида для внутривенного введения и ее применение
HK1176318A1 (en) Injection device
EA200501105A1 (ru) Фармацевтическая композиция
MX2009005798A (es) Recuperacion de apoplejia.
JP2018502856A5 (es)
AR062112A1 (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina
MX2023013040A (es) Composiciones y metodos para el tratamiento de la depresion.
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
PE20070645A1 (es) Compuestos heterociclicos como moduladores de la beta-secretasa
RU2015114566A (ru) Способы лечения гепатита с

Legal Events

Date Code Title Description
FD Application declared void or lapsed